Actively Recruiting

Phase 2
Age: 35Years - 75Years
All Genders
NCT06485843

An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint

Led by Ageless Biotech, Inc. · Updated on 2025-09-18

400

Participants Needed

1

Research Sites

188 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.

CONDITIONS

Official Title

An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint

Who Can Participate

Age: 35Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults between the ages of 35 and 75 years with a Body Mass Index (BMI) less than 39 kg/m2
  • Ambulatory and in good general health
  • Willing and able to comply with study procedures and visit schedules
  • Willing to avoid protocol-restricted treatments from screening through end-of-treatment
  • Kellgren-Lawrence grade 3 or 4 for osteoarthritis of the knee
  • No significant abnormalities in medical history, physical exam, vital signs, or lab tests
  • Females of reproductive potential must use effective contraception for at least 1 month before screening and during the study; negative pregnancy test required
  • Males of reproductive potential must use condoms or other effective contraception methods
Not Eligible

You will not qualify if you...

  • Infection of the target knee joint
  • Previous surgery for osteoarthritis in the target knee joint
  • Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis related to inflammatory bowel disease
  • Uncontrolled heart disease or hypertension despite treatment with more than three antihypertensive drugs
  • Serious medical conditions other than cardiovascular disease
  • Autoimmune diseases or history of such diseases
  • Infection requiring intravenous antibiotics within 30 days before screening
  • History of mental disorder or epilepsy
  • Alcohol abuse (10 times a week) or smoking 25 cigarettes a day
  • Cancer diagnosis within 5 years before screening
  • Participation in another clinical trial within 6 months before screening
  • Use of immunosuppressants such as cyclosporin A or azathioprine within 6 weeks before screening
  • Intra-articular injections like sodium hyaluronate within 6 months before screening
  • Active infection or crystal disease in the index joint within 1 month before screening
  • Fracture in the index limb or related complications within 12 months before screening
  • Joint instability or acute dislocation within 12 months before screening
  • Planned or expected joint surgery during the study
  • Presence of surgical hardware or foreign body in the index joint
  • Surgery or arthroscopy of the index joint within 12 months before screening
  • Intra-articular treatment with corticosteroids, biologics, or investigational therapy within 6 months before screening
  • Serious life-threatening conditions
  • Allergies to anesthesia
  • Currently breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Orthopedic & Sports Medicine Institute of Las Vegas

Las Vegas, Nevada, United States, 89117

Actively Recruiting

Loading map...

Research Team

V

Vince Liguori

CONTACT

M

Mukesh Kumar, PhD RAC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here